A PBM audit letter that isolates a pharmacy's insulin, test strip, lancet, and continuous glucose monitor (CGM) claims is rarely a routine records request. These claims carry some of the highest per-patient volume in a pharmacy's book, which is exactly what pulls them into a PBM audit's sampling model. A single quantity that exceeds the plan's standard limit, dispensed without a documented override, can be extrapolated across the full lookback period into a six-figure recoupment demand.
Why Diabetic Supply Claims Draw Audit Attention
Insulin, test strips, lancets, and CGM sensors generate consistently high claim volume, and utilization is the signal PBM audit teams build their sampling models around. A patient titrating an insulin dose, testing more often after a diagnosis change, or replacing a failed CGM sensor can generate a quantity that exceeds the plan's standard limit in a given month. When that quantity is entered with a manual override, or without one, the claim lands on the auditor's high-utilization report long before the pharmacist sees any consequence at the point of sale, and a pattern of these claims across a pharmacy's book can also feed the utilization data a PBM cites toward network termination.
Documentation That Defends a High-Utilization Claim
Medicare's glucose monitor coverage policy sets the reference benchmark most PBM point-of-sale edits are built around: up to 300 test strips and 300 lancets every three months for insulin-treated patients, roughly 100 a month, and up to 100 every three months for patients not on insulin. Quantities above that threshold require the prescriber's dated order and medical record documentation establishing the medical necessity of the higher quantity, along with evidence the patient is actually testing at the frequency the quantity implies, such as a glucose log or a specific narrative statement. A pharmacy that keeps this documentation on file at the time of dispensing, not reconstructed after the audit notice arrives, has what it needs to survive the finding at the desk-audit stage or on audit appeal.
Findings PBM Auditors Commonly Cite
Three finding types account for most diabetic supply audit results. The first is a quantity that exceeds the plan's limit with no override or medical necessity documentation on file. The second is a days-supply calculation error, most often on CGM sensor claims: Medicare's non-adjunctive CGM supply allowance is billed as one unit of service per 30 days, up to three units for a 90-day supply, and a claim submitted before the prior supply period has run its course reads as a billing error even when the patient's device genuinely failed early. The third is a refill-too-soon pattern, where a pharmacy's own dispensing history looks, on paper, like duplicate therapy rather than a documented dose increase.
A refill-too-soon flag on a CGM sensor claim can read exactly like fraud until the days-supply math and the titration note are on the table.
These finding patterns recur across PBMs. Our companion pieces on Humana pharmacy audits, MedImpact audit findings, and Navitus audits show how the same documentation gaps play out elsewhere.
Why Early Legal Counsel Is Critical
It is critical that pharmacy owners promptly retain experienced healthcare defense counsel upon receiving a PBM audit notice, a documentation request tied to diabetic supply claims, or a recoupment demand. Early legal intervention can protect the pharmacy's rights, ensure the response addresses both the quantity-limit documentation and the days-supply calculation at issue, avoid inadvertent admissions, and preserve defenses that may otherwise be lost. Delaying representation can significantly affect the outcome of the audit.
How Health Law Alliance Can Help
Health Law Alliance defends pharmacies against PBM audit findings tied to insulin, test strip, lancet, and CGM claims, including the quantity-limit and days-supply disputes that drive the largest diabetic supply recoupment demands. Our bench includes a former federal prosecutor and a former senior OptumRx executive, background that shapes how we evaluate which flagged claims are defensible and which call for an early settlement posture. If your pharmacy has received an audit notice involving diabetic supply claims, contact us for a free, confidential consultation.
